AUTHORS
Hongyan Tong, MD, PhD, Zhijian Xiao2, Min Zhang3, Praneeth Baratam4, Joshua F. Zeidner, MD5, Lina Zhang, MD6, Ramzi Abboud, MD7, Fei Li, MD8, Uma Borate, MBBS, MSc9, Hao Jiang10, Liangming Ma, MD11, Wanxing board Chai-Ho, MD12, Zheng Ge, MD, PhD13, Qike Zhang, MD14, Sujun Gao, MD15, Jinhai Ren, MD16, Najeff Waseem, MD17, Christopher Benton, MD18, Mendel Goldfinger, MD19, Yazan F. Madanat, MD20, Mingxiu Hu21, Zhongmin Maxwell Wang22, Baiyong Li23, Michelle Y. Xia24, Amer M. Zeidan, MD25
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 MUSC Hollings Cancer Center, Charleston, United States
5 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, United States
6 Henan Cancer Hospital, Zhengzhou, China
7 Washington University School of Medicine in St. Louis, St. Louis, United States
8 The First Affiliated Hospital of Nanchang University, Nanchang, China
9 The Ohio State University, Columbus, United States
10 Peking University People's Hospital, Beijing, China
11 Shanxi Bethune Hospital, Taiyuan, China
12 UCLA Ronald Reagan Medical Center, Los Angeles, United States
13 Zhongda Hospital Southeast University, Nanjing, China
14 Gansu Provincial Hospital, Lanzhou, China
15 The First Hospital of Jilin University, Changchun, China
16 The Second Hospital of Hebei Medical University, Shijiazhuang, China
17 Maryland Oncology Hematology (SCRI), Hyattsville, United States
18 Rocky Mountain Cancer Center (SCRI), Denver, United States
19 Montefiore Einstein Comprehensive Cancer Center, Bronx, United States
20 UT Southwestern Medical Center, Dallas, United States
21 Akeso Biopharma, Inc., Zhongshan, China
22 Akeso Biopharma, Inc., Zhongshan, China
23 Akeso Biopharma, Inc., Zhongshan, China
24 Akeso Biopharma, Inc., Zhongshan, China
25 Yale Cancer Center, New Haven, United States
ABSTRACT
Background: ?
MDS are heterogeneous clonal hematopoietic disorders, and HR-MDS are characterized by a dismal prognosis. Hypomethylating agents, particularly azacitidine (AZA), constitute the standard of care for HR-MDS; however, clinical outcomes remain suboptimal, and therefore novel effective therapies are urgently needed. AK117 (ligufalimab) is a next-generation, humanized IgG4 monoclonal antibody targeting CD47—a key “don’t eat me” signal—thereby potentiating macrophage-mediated phagocytosis. Unlike magrolimab (a first generation anti-CD47 antibody), AK117 possesses a unique binding geometry that precludes bivalent engagement? of red blood cells (RBCs). This mechanism avoids? RBCs bridging and hemagglutination, thereby eliminating? the need for a priming dose or intensive anemia monitoring (Qu T et al. J Immunother Cancer. 2022). A prior Phase 1b study from China established a manageable safety profile and promising efficacy for the AK117-AZA combination in ND HR-MDS (Miao M et al. ASH. 2023). We therefore initiated a new randomized phase 2 study to optimize the dose selection and extend the findings to USA-based patients.
Methods:
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study (NCT06196203) designed to further optimize the dose of AK117. Approximately 90 patients with ND HR-MDS (Revised International Prognostic Scoring System [IPSS-R] score ≥3.5) from China and USA were randomized 1:1:1 to receive AK117 30 mg/kg Q2W, AK117 20 mg/kg Q2W, or placebo, all in combination with AZA (75 mg/m², Days 1–7, Q4W). Stratification was by IPSS-R score (≤4.5, >4.5–6, >6). The primary endpoint is complete remission (CR) rate per International Working Group (IWG) 2023 criteria (Zeidan A et al, Blood. 2023). Key secondary endpoints include event-free survival (EFS) and overall survival (OS). Here we report for the first time the preliminary efficacy and safety data.
Results:
As of July 1, 2026, 91 patients (N=45 China, N=46, USA) were randomized (AK117 30 mg/kg, n=31; AK117 20 mg/kg, n=29; placebo, n=31). Baseline characteristics, including age, sex, ECOG performance status, WHO classification, and IPSS-R category, were generally balanced across arms. The AK117 30 mg/kg cohort had a higher RBCs transfusion dependence rate (61.3% vs. 41.4% and 41.9%).
Among 73 evaluable patients (those with at least one post-baseline efficacy assessment), CR rates were 12.0% with AK117 30 mg/kg, 30.4% with AK117 20 mg/kg, and 12.0% with placebo. Overall response rates (ORR) were 52.0%, 52.2% and 44.0%; composite CR rates were 32.0%, 43.5%, and 16.0%, respectively. In the full analysis set, with a median follow-up of 20.4 months, median EFS and OS were 8.6 and 13.9 months, in the AK117 30 mg/kg arm; in the AK117 20 mg/kg and placebo arms, median EFS was 13.7 months vs. 8.5 months, respectively. Median OS was not reached in the 20 mg/kg arm (24-month OS rate of 63.3% and thus median OS will be longer than 24 months) vs. 19.5 months in the placebo arm. The incidence of overall treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) were comparable across all treatment arms. The most frequently reported TRAEs—decreased white blood cell, platelet, and neutrophil counts, and anemia—aligned with both MDS-associated cytopenias and expected AZA toxicities, with similar incidence across groups. TRAEs led to permanent treatment discontinuation in 2, 1, and 2 patients in the 30 mg/kg AK117, 20 mg/kg AK117, and placebo arms, respectively. No TRAE-related deaths occurred in either AK117 treatment arm. Overall, no new AK117-related safety signals were identified.
Conclusions:
AK117 in combination with AZA demonstrates a manageable and tolerable safety profile in patients with newly diagnosed HR-MDS. The 20 mg/kg Q2W dose of AK117 shows promising efficacy signals, including numerically higher CR rate and a trend toward improved OS and EFS compared with both the 30 mg/kg dose and the placebo arm. The worse outcomes in the 30mg/kg could potentially be explained by a worse prognostic baseline profile and potentially by hook effect of the higher dose compromising biologic activity. Promising results were also observed in an acute myeloid leukemia trial with AK117 20 mg/kg Q2W in combination with AZA and venetoclax (Jie J et al. EHA 2026). Based on these preliminary findings, AK117 20 mg/kg Q2W is proposed as the recommended dose for future confirmatory trials.
DISCLOSURES
Amer M. Zeidan, MD: AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony); AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony)